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degeneration or incompetence, aortic root dilatation with aortic annulus enlargement, or both. These anatomical differences pose particular challenges for TAVI, which we will discuss later. Figure 1 depicts the main anatomical differences between AS and AR.
Current Management of Aortic Regurgitation
Prevalence of AR increases with age and it affects about 13% of patients with isolated, native left-sided valvular heart disease. 21 Symptoms related to AR tend to appear late in the history of the disease, once LV dilatation and systolic dysfunction have set in. Patients with severe AR and an ejection fraction <30% have an annual mortality risk of 20%, but unfortunately only 5% of these patients are given SAVR according to data from the Euro Heart Survey on Valvular Heart Disease. 21 According to current European and US guidelines, patients with symptomatic moderate/severe AR and decreased LV systolic function (<50%) or severe LV dilatation (LV end-systolic diameter >50 mm; LV end-diastolic diameter >65-70 mm; LV end-systolic volume index >45 ml/m 2 ) should be considered for SAVR. 2, 3 Nonetheless, there is a high-risk subgroup who are inoperable and who could be considered for TAVI, taking into account the multiple procedural challenges and the fact that it still is an off-label indication. 22 To date, the standard of care for severe NPAR is SAVR with TAVI emerging as an option for high-risk or inoperable patients.
Technical Challenges During TAVI for NPAR
The main challenge that interventionists face during TAVI for NPAR is the absence of annular and leaflet calcification, which is necessary for device anchoring and stabilisation during deployment. The lack of calcium, the increased stroke volume secondary to severe AR and the presence of aortic root dilatation makes device positioning and deployment very difficult and there is a predisposition to embolisation or malposition of the prosthesis with subsequent moderate to severe post-procedural AR (associated with worst clinical outcomes). 23 Valve migration can occur to the aorta or deep into the LV up to several hours after implantation. 24 Valve oversizing has been proposed to reduce the risk of valve migration. Published data recommend a 15-20% oversize when selecting the THV size with the caution not to oversize beyond 20% due to the risk of annular rupture and conduction system abnormalities. The JenaValve, a self-expanding, 32Fr transapical valve with three integrated locators was the first dedicated device to get the CE mark for NPAR based on its anatomically correct positioning in the native cusps and clipping of the THV onto the native leaflets. 36, 37 Since June 2016, the transapical system is no longer available but development of a new generation transfemoral system is underway and has been used successfully for NPAR in a first-in-human case report in 2017. 38 The
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THV Devices Available for NPAR
Longterm Safety and Performance of the JenaValve (JUPITER) registry showed a procedural success rate of 96.7% with 0% incidence of valve malposition and moderate to severe post-procedural AR. 39 Another NPAR-dedicated second generation TAVI device is the J-Valve, which has a unique system composed of three U-shape graspers that facilitate intuitive self-positioning implantation providing axial and radial fixation by embracing the native valve leaflets. A successful first-in-human implantation was reported in 2015 but currently, the device is only available in Asia. 40 Table 1 shows the different THVs available for NPAR.
TAVI for NPAR: Evidence on Early Generation Devices
The first use of TAVI for NPAR was reported by Roy et al. in 2013 and included the retrospective analysis of 43 patients at 14 centres who had TAVI for severe inoperable NPAR. All cases used CoreValve prosthesis and as part of the procedure protocol two pigtail catheters in different sinuses of Valsalva were used to guide THV delivery under rapid pacing. Results included a 97.7% success rate (according to protocol and not VARC-2 guidelines), in 18.6% of the cases a second valve was required during the index procedure for residual AR (all of which had absent valve calcification) and the one-year all-cause mortality was 21.4%. 41 Multiple studies followed using early generation devices (CoreValve being the most used followed by Sapien/Sapien XT, JenaValve, Direct flow and ACURATE TA), and in 2016 Franzone et al. published a meta-analysis of 13 studies with a total of 237 severe inoperable NPAR patients without AS treated with TAVI. [42] [43] [44] In 80% of the cases a self-expandable valve was used and less than 25% of the cases were treated with devices approved for AR. Device success ranged from 77% to 100% with a 7% incidence of second valve implant due to either device migration or severe post-procedural AR. The primary endpoint of all-cause mortality at 30 days ranged from 0 to 30% with a summary estimate rate of 7%. Moderate to severe postprocedural AR was reported in up to 88% of patients with a summary estimate rate of 9%. 45 The JenaValve subgroup had a 0% incidence of moderate to severe post-procedural AR. Given the heterogeneity of the groups and procedural aspects, no solid conclusions in terms of safety and efficacy can be drawn from these initial experiences but all of them showed that TAVI for NPAR is complex, with success rates below those reported for AS and a high incidence of valve malposition and moderate to severe post-procedural AR.
TAVI for NPAR: Evidence on New Generation Devices
New 
and cardiovascular mortality were significantly lower with NGD (12.7% versus 24.4%; 4.2% versus 18.8% and 9.6% versus 23.6%, respectively) when compared with EGD. They also found that the absence of calcium or the presence of mild calcification was associated with less frequent device success with EGD but not with NGD. A larger annulus (>25.2mm) was associated with less frequent device success either with EGD or NGD. Finally, they showed that a higher degree of perimeter oversizing index (>15%) was associated with less frequent moderate to severe AR. 49 Sawaya et al. performed a retrospective analysis of 78 patients with severe NPAR treated with TAVI. The majority of cases were done under general anaesthesia via transfemoral access with CoreValve; given its radial force at both the annular level and ascending aorta and also because it could be significantly oversized without risk of annular rupture. Results were consistent with those that we have previously described. NGD showed a lower incidence of valve malposition, a lower degree of AR and cardiovascular mortality versus EGD. They also found that a BMI <20kg/m 2 , Society of Thoracic Surgeons score >8%, major vascular complication or new left bundle branch block, and more than moderate AR were independent predictors of mortality and New York Heart Association III-IV at 30 days after TAVI for NPAR. 50 All of these findings were confirmed in a recent meta-analysis. 51 Table 2 summarises the main results of these three studies.
Interventional Tips and Tricks for TAVI for NPAR
The following recommendations are made based on personal experience and information gathered from published cases. 
Conclusion
Patients with NPAR who are candidates for TAVI tend to be in a poorer clinical condition than many contemporary AS patients, due
to LV dilatation and dysfunction. These facts alongside the technical difficulties met during the procedure and the lack of transfemoral dedicated devices make TAVI for NPAR an 'off-label' treatment. Even New dedicated devices are being designed and those available are evolving to transfemoral as we continue to gain experience of using non-dedicated devices for this patient group. Nonetheless, TAVI for NPAR has to be considered the treatment of choice for inoperable severe AR patients because it offers a better prognosis than optimal medical treatment. TAVI has been established for inoperable or high-risk patients, but we need to improve. TAVI is not yet the standard of care for NPAR, but it is likely to be established as such in time.
